Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 1044 results for criteria

  1. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  2. Thyroid disease: assessment and management (NG145)

    This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.

  3. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  4. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  5. Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  6. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

  7. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  8. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  9. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  10. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  11. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  12. Upadacitinib for treating severe rheumatoid arthritis (TA665)

    Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.

  13. Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

    Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.

  14. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

  15. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.